Design Therapeutics, Inc. (DSGN) Stock

Design Therapeutics, Inc. (DSGN) is a Healthcare stock trading at $12.40 (as of 2026-06-18), with a market capitalization of $654.55M and a trailing P/E of -9.1. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Design Therapeutics, Inc. is a preclinical-stage biopharmaceutical company developing therapies for genetic diseases driven by nucleotide repeat expansions. Its pipeline includes programs for Friedreich Ataxia and Myotonic Dystrophy Type-1, and it is also developing a GeneTAC product candidate portfolio targeting other repeat-expansion monogenic conditions.

Valuation — source: SEC EDGAR (first-party)
Price$12.40
Market Cap$654.55M
P/E Ratio-9.1
EV / EBITDA-8.6
Price / Book3.14
DCF Value (model)$-14.79
DCF Upside vs Price-219.3%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$0.00
Return on Equity-32.0%
Current Ratio22.28
Revenue Growth (YoY)-27.8%
EPS Growth (YoY)30.4%
FCF Growth (YoY)26.7%
Financial Health — source: SEC EDGAR
Altman Z-Score31.61 (safe)
Valuation vs Sector & Industry
Stock P/E-9.1
Sector P/E (Healthcare)20.9
Industry P/E (Pharmaceutical Products)17.0
vs Sector-143.8%
vs Industry-153.7%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderSR One Capital Management, LP ($69.44M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOPratik Shah
Employees56
CountryUS
IPO Date2021-03-29

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • SELLAS Life Sciences Group, Inc. (SLS)
  • Corvus Pharmaceuticals, Inc. (CRVS)
  • Evommune, Inc. (EVMN)
  • Alto Neuroscience, Inc. (ANRO)
  • Kyverna Therapeutics, Inc. (KYTX)
  • LB Pharmaceuticals Inc Common Stock (LBRX)
  • Ironwood Pharmaceuticals, Inc. (IRWD)
  • Assembly Biosciences, Inc. (ASMB)
DSGN earnings history · DSGN institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.